MXCT · Maxcyte, Inc.
Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| EBITDA non-GAAP | -$5.1M | first quarter of 2026 | — |
| Non-GAAP adjusted gross margin non-GAAP | 78% | first quarter of 2026 | — |
| SeQure total revenue | $600K | Q1 2026 call | — |
| share repurchase program authorization | $10M | Q1 2026 call | — |
| SPL partners | 29 | Q1 2026 call | — |
| SPL programs currently in the clinic | 12 | Q1 2026 call | — |
| total future pre-commercial milestone opportunity | $100M | Q1 2026 call | — |
| Total cash, cash equivalents and investments | $155.6M | As of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MXCT
this stock
Maxcyte, Inc.
|
$132.83M | -20.0% | -14.5% | — | 1.4% |
|
ABT
Abbott Laboratories
|
$175.37B | -19.2% | +5.7% | 28.2 | 1.3% |
|
SYK
Stryker Corp
|
$122.63B | -8.7% | +11.2% | 37.0 | 1.8% |
|
MDT
Medtronic plc
|
$106.50B | -12.7% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.44B | -53.8% | +5.5% | 18.4 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MXCT | -6.8% | +9.7% | +6.9% | +0.8% | -20.0% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -5.2% | +9.4% | -0.9% | +1.3% | -29.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.